These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 37880788)
1. The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab. Mallardo D; Woodford R; Menzies AM; Zimmer L; Williamson A; Ramelyte E; Dimitriou F; Wicky A; Wallace R; Mallardo M; Cortellini A; Budillon A; Atkinson V; Sandhu S; Olivier M; Dummer R; Lorigan P; Schadendorf D; Long GV; Simeone E; Ascierto PA J Transl Med; 2023 Oct; 21(1):753. PubMed ID: 37880788 [TBL] [Abstract][Full Text] [Related]
2. Activity and safety of first-line treatments for advanced melanoma: A network meta-analysis. Boutros A; Tanda ET; Croce E; Catalano F; Ceppi M; Bruzzone M; Cecchi F; Arecco L; Fraguglia M; Pronzato P; Genova C; Del Mastro L; Lambertini M; Spagnolo F Eur J Cancer; 2023 Jul; 188():64-79. PubMed ID: 37196485 [TBL] [Abstract][Full Text] [Related]
3. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. Long GV; Stephen Hodi F; Lipson EJ; Schadendorf D; Ascierto PA; Matamala L; Salman P; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; Janoski De Menezes J; Dalle S; Arance A; Grob JJ; Keidel S; Shaikh A; Sobiesk AM; Dolfi S; Tawbi HA NEJM Evid; 2023 Apr; 2(4):EVIDoa2200239. PubMed ID: 38320023 [TBL] [Abstract][Full Text] [Related]
4. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV; N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285 [TBL] [Abstract][Full Text] [Related]
5. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG. Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571 [TBL] [Abstract][Full Text] [Related]
6. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma. Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905 [TBL] [Abstract][Full Text] [Related]
7. Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma. van Not OJ; Verheijden RJ; van den Eertwegh AJM; Haanen JBAG; Aarts MJB; van den Berkmortel FWPJ; Blank CU; Boers-Sonderen MJ; de Groot JB; Hospers GAP; Kamphuis AM; Kapiteijn E; May AM; de Meza MM; Piersma D; van Rijn R; Stevense-den Boer MA; van der Veldt AAM; Vreugdenhil G; Blokx WAM; Wouters MJM; Suijkerbuijk KPM JAMA Oncol; 2022 Dec; 8(12):1794-1801. PubMed ID: 36301521 [TBL] [Abstract][Full Text] [Related]
8. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma. Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680 [TBL] [Abstract][Full Text] [Related]
9. LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials. Zhao BW; Zhang FY; Wang Y; Chen GM; Nie M; Zhao ZK; Chen XJ; Jiang KM; Nie RC; Chen YB Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291763 [No Abstract] [Full Text] [Related]
10. Complete Remission of Metastatic Melanoma of the Scalp Following Treatment With Nivolumab Plus Relatlimab. McMinn ME; Brister KA; Orr WS; Sheehan NT; Christopher WO Am Surg; 2024 Aug; 90(8):2078-2079. PubMed ID: 38553440 [TBL] [Abstract][Full Text] [Related]
11. Nivolumab Plus Relatlimab: First Approval. Paik J Drugs; 2022 Jun; 82(8):925-931. PubMed ID: 35543970 [TBL] [Abstract][Full Text] [Related]
12. The Latest Option: Nivolumab and Relatlimab in Advanced Melanoma. Albrecht LJ; Livingstone E; Zimmer L; Schadendorf D Curr Oncol Rep; 2023 Jun; 25(6):647-657. PubMed ID: 37004702 [TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data. Ossato A; Damuzzo V; Baldo P; Mengato D; Chiumente M; Messori A Cancer Med; 2023 Feb; 12(3):2155-2165. PubMed ID: 35920297 [TBL] [Abstract][Full Text] [Related]
14. First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. Long GV; Lipson EJ; Hodi FS; Ascierto PA; Larkin J; Lao C; Grob JJ; Ejzykowicz F; Moshyk A; Garcia-Horton V; Zhou ZY; Xin Y; Palaia J; McDonald L; Keidel S; Salvatore A; Patel D; Sakkal LA; Tawbi H; Schadendorf D J Clin Oncol; 2024 Aug; ():JCO2401125. PubMed ID: 39137386 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma. Phillips AL; Reeves DJ Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952 [TBL] [Abstract][Full Text] [Related]
16. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). Piulats JM; Espinosa E; de la Cruz Merino L; Varela M; Alonso Carrión L; Martín-Algarra S; López Castro R; Curiel T; Rodríguez-Abreu D; Redrado M; Gomà M; Rullán AJ; Calvo González A; Berrocal-Jaime A J Clin Oncol; 2021 Feb; 39(6):586-598. PubMed ID: 33417511 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112 [TBL] [Abstract][Full Text] [Related]
18. Exploratory analysis of clinical benefit of ipilimumab and nivolumab treatment in patients with metastatic melanoma from a single institution. Vila CM; Moreno FA; Estébanez MM; Ares GR; Villacampa G; Dashti P; Oberoi HS; Martin-Huertas R; Jares P; Alos L; Teixido C; Rull R; Sanchez M; Malvehy J; Carcelero E; Valduvieco I; Fernandez AA Clin Transl Oncol; 2022 Feb; 24(2):319-330. PubMed ID: 34420138 [TBL] [Abstract][Full Text] [Related]
19. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis. Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531 [TBL] [Abstract][Full Text] [Related]
20. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]